Form 8-K

8-K — BIOMARIN PHARMACEUTICAL INC

Accession: 0001048477-26-000015

Filed: 2026-08-06

Period: 2026-08-06

CIK: 0001048477

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — bmrn-20260806.htm (Primary)

EX-99.1 (earningsrelease-6aug26ex991.htm)

GRAPHIC (imagea.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: bmrn-20260806.htm · Sequence: 1

bmrn-20260806

0001048477false00010484772026-05-042026-05-0400010484772026-08-062026-08-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 6, 2026

BioMarin Pharmaceutical Inc.

(Exact name of registrant as specified in its charter)

Delaware

000-26727

68-0397820

(State or other jurisdiction of incorporation or organization)

(Commission File Number)

(I.R.S. Employer Identification No.)

770 Lindaro Street

San Rafael

California

94901

(Address of Principal Executive Offices)

(Zip Code)

(415) 506-6700

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered

Common Stock, par value $0.001 BMRN The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 6, 2026, BioMarin Pharmaceutical Inc. (the Company) announced financial results for its second quarter ended June 30, 2026. The Company’s press release issued on August 6, 2026 is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

The information in this Form 8-K, including in the press release furnished as Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities under that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the Securities Act), nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number Description

99.1

Press Release of the Company dated August 6, 2026

104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

BioMarin Pharmaceutical Inc.,

a Delaware corporation

Date: August 6, 2026

By: /s/ G. Eric Davis

G. Eric Davis

Executive Vice President, Chief Legal Officer

EX-99.1

Filename: earningsrelease-6aug26ex991.htm · Sequence: 2

Document

Exhibit 99.1

Contact:

Investors: Media:

Traci McCarty Marni Kottle

BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc.

(415) 455-7558 (650) 374-2803

BioMarin Reports Second Quarter 2026 Financial and Operating Results

Second Quarter 2026 Total Revenues Increased 20% Year-over-year to $990 million

Stronger Growth Expectations Drive Increased Guidance for Full-year 2026 Total Revenues, VOXZOGO®, and Non-GAAP Diluted Earnings Per Share (EPS)

Addition of GALAFOLD® and POMBILITI® + OPFOLDA®, with Cost Synergies, Expected to Accelerate Revenue Growth, Non-GAAP Diluted EPS Accretion, Non-GAAP Operating Margin Expansion, and Operating Cash Flow through the Mid-2030s

Conference Call and Webcast Scheduled Today at 4:30 p.m. ET

SAN RAFAEL, Calif., August 6, 2026 – BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the second quarter ended June 30, 2026.

"This quarter, we executed strongly across our portfolio while rapidly integrating Amicus into BioMarin's operations and advancing plans to accelerate growth for GALAFOLD and POMBILITI + OPFOLDA, and extending the benefit of these medicines to more patients worldwide," said Alexander Hardy, President and Chief Executive Officer of BioMarin. “Strong global demand led us to increase full-year VOXZOGO revenue guidance to at least $1 billion in 2026. Adding to this momentum is the opportunity to advance our second potential indication with VOXZOGO, hypochondroplasia, based on recent pivotal data that exceeded our expectations.” Mr. Hardy added, “With our larger, more diversified commercial portfolio of innovative medicines, we are positioned to deliver additional growth and increased profitability. We expect strong execution through the remainder of 2026, bringing together our expanded portfolio, scale and disciplined integration efforts to reach more patients living with serious genetic conditions around the world.”

2026 Business and Pipeline Highlights

Innovation

•BioMarin recently submitted its supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the approval of VOXZOGO for the treatment of hypochondroplasia. If approved, VOXZOGO would be the first targeted therapy for the treatment of hypochondroplasia, with a potential 2027 launch. The company plans to provide an update on the application status as part of its third quarter earnings update.

•In May, the company announced that the Phase 3 CANOPY-HCH-3 study of VOXZOGO in children with hypochondroplasia met its primary endpoint, with a statistically significant increase in annualized growth velocity (AGV) at week 52 versus placebo (LS mean difference +2.33 cm/yr, p<0.0001), along with significant improvements in standing height, height Z-score, and the key secondary endpoint of arm span. The full Phase 3 dataset will be shared in a late-breaking oral presentation at the European Society for Paediatric Endocrinology Annual Meeting in September.

•In June, at the Endocrine Society Annual Meeting (ENDO 2026), a Phase 2 investigator-sponsored three-year extension study of VOXZOGO in 13 children with hypochondroplasia showed sustained improvements in growth with a favorable safety profile. Mean AGV increased from 4.27 cm/year at baseline to 7.24 cm/year at year one (p<0.001) and remained above baseline through year three, with mean height standard deviation score (SDS) improving 0.72 over the three years.

•Also at ENDO 2026, the company presented Phase 1 data for BMN 333, BioMarin's long-acting C-type natriuretic peptide (CNP) for achondroplasia. In a single-ascending-dose study in healthy adults, BMN 333 demonstrated sustained exposure supporting weekly dosing and was well tolerated, with free CNP exposure at the highest dose more than 13-fold that of another long-acting CNP agent, reflecting its potential to become a new standard of care in achondroplasia. The Phase 2/3 study is enrolling, with a data update expected in 2027.

•In July, BioMarin announced that the FDA accepted its sNDA for full approval of VOXZOGO in children with achondroplasia, with a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2027.

•In the second quarter, the European Commission approved PALYNZIQ® for adolescents 12 years and older with phenylketonuria (PKU). PALYNZIQ is the only therapy that enables people with PKU to reach physiologic Phe levels while reducing dietary restrictions, regardless of severity.

•During the quarter, BioMarin added BMN 820 (formerly DMX-200) to its portfolio, a first-in-class oral CCR2 inhibitor for focal segmental glomerulosclerosis (FSGS) for which BioMarin holds exclusive U.S. commercialization rights. BMN 820 has the potential to treat a broad FSGS population, regardless of nephrotic syndrome status, and represents a U.S. total addressable patient population of approximately 30,000. The Phase 3 ACTION 3 trial is ongoing, with pivotal data expected in 2028.

•BMN 351, BioMarin's Phase 1/2 candidate for Duchenne muscular dystrophy, continued in development. The company expects to provide a program update by year-end.

•Following the pivotal ENERGY 3 trial results, previously announced in May, in which BMN 401 did not meet one of its two co-primary endpoints for the treatment of ENPP1 deficiency, BioMarin has now made the decision to discontinue development of BMN 401 across all indications.

•In July, BioMarin and the n-Lorem Foundation entered a collaboration and global exclusive license agreement to develop a first-in-disease antisense oligonucleotide (ASO) medicine for ReNU syndrome, a serious, rare neurodevelopmental condition with no approved targeted therapies. ReNU syndrome has an expected global population of approximately 100,000.

Growth

•BioMarin expects peak revenue for GALAFOLD to be approximately $1.4 billion by the mid-2030s and for POMBILITI + OPFOLDA to be approximately $1.2 billion by the mid-to-late-2030s. BioMarin expects these high growth therapies to benefit from its global scale and proven commercial capabilities.

•Metabolic Conditions (formerly Enzyme Therapies) revenue grew 25% Y/Y in the second quarter of 2026, driven by the additions of GALAFOLD and POMBILITI + OPFOLDA and continued strength from PALYNZIQ. The number of patients on therapy grew across all BioMarin-marketed therapies, both Y/Y and sequentially.

•Strong U.S. and global demand led to increased full-year 2026 VOXZOGO revenue guidance to a low end of $1 billion. The number of children being treated with VOXZOGO globally increased by more than 20% Y/Y in the second quarter. In the U.S., the majority of new patient starts were under two years of age, and the region drove approximately 25% of total VOXZOGO revenue during the quarter.

Value Commitment

•As part of the acquisition of Amicus, which closed on April 27, 2026, the company identified approximately $280 million of cost reductions on a GAAP basis, and approximately $220 million of cost reductions on a Non-GAAP basis, expected to be fully realized in 2028, representing an approximately 50% reduction from Amicus-reported 2025 GAAP and Non-GAAP operating expenses, respectively. Synergies reflect a reduction of Amicus’ legacy labor costs and external spend and are expected to be largely driven by general and administrative functions, with the large majority of sales and marketing capabilities retained to support continued commercial growth.

•GALAFOLD and POMBILITI + OPFOLDA, combined, are expected to reach over 60% Non-GAAP Operating Margin by 2030.

•The company is targeting gross leverage below 2.5 times by mid-year 2027, an acceleration by approximately one year of prior timeline guidance provided at deal announcement, supported by profitability growth of the combined company.

Second Quarter 2026 Financial Highlights

•Total Revenues for the second quarter of 2026 were $990 million, an increase of $165 million compared to the same period in 2025, primarily driven by revenues from GALAFOLD and POMBILITI + OPFOLDA, which were acquired from Amicus on April 27, 2026, as well as new patients initiating VOXZOGO therapy across all regions and growth in U.S. patients treated with PALYNZIQ. These increases were partially offset by lower VIMIZIM® revenue due to the timing of large government orders outside the U.S. and lower ALDURAZYME® sales volume due to the timing of order fulfillment to Sanofi.

•GAAP Net Income for the second quarter of 2026 decreased to $45 million compared to $241 million for the same period in 2025. The decrease was primarily driven by the acquisition of Amicus, including integration and restructuring costs, intangible asset amortization, interest expense from debt issued to finance a portion of the transaction, and amortization of inventory fair value step-up. Other drivers included higher sales and marketing spend to support newly acquired products and global expansion of VOXZOGO and higher Research and Development (R&D) spend related to BMN 401, which was acquired in the third quarter of 2025, partially offset by higher gross profit driven by revenue growth as described above.

•Non-GAAP Income for the second quarter of 2026 decreased to $236 million compared to $282 million for the same period in 2025. The decrease was primarily driven by higher interest expense, higher sales and marketing spend to support newly acquired products and global expansion of VOXZOGO, and higher R&D spend related to BMN 401, partially offset by higher gross profit driven by revenue growth as described above.

Financial Highlights (in millions of U.S. dollars, except per share data, unaudited)

Three Months Ended

June 30, Six Months Ended

June 30,

2026 2025 % Change 2026 2025 % Change

Total Revenues $990 $825 20% $1,756 $1,571 12%

Net Product Revenues by Product:

VOXZOGO $253 $221 14% $472 $435 9%

Metabolic Conditions:

VIMIZIM $194 $215 (10)% $405 $404 —%

NAGLAZYME®

135 129 5% 265 243 9%

PALYNZIQ 135 106 27% 225 199 13%

GALAFOLD #N/A #N/A NM #N/A #N/A NM

BRINEURA®

51 49 4% 98 89 10%

ALDURAZYME 44 56 (21)% 80 105 (24)%

POMBILITI + OPFOLDA #N/A #N/A NM #N/A #N/A NM

Total Metabolic Conditions Revenue #N/A #N/A #N/A #N/A #N/A #N/A

KUVAN®

$24 $27 (11)% $48 $52 (8)%

ROCTAVIAN®(1)

$12 $9 33% $14 $20 (30)%

GAAP Net Income

$45 $241 (81)% $150 $426 (65)%

Non-GAAP Income (2)

$236 $282 (16)% $385 $502 (23)%

GAAP Operating Margin % (3)

11.2% 33.5% 13.7% 31.9%

Non-GAAP Operating Margin % (2)

36.4% 39.9% 31.0% 37.9%

GAAP Diluted EPS

$0.23 $1.23 (81)% $0.77 $2.19 (65)%

Non-GAAP Diluted EPS (2)

$1.20 $1.44 (17)% $1.96 $2.57 (24)%

NM Percentage change is not meaningful for products acquired from Amicus on April 27, 2026.

(1) In 2026, the company announced that it will no longer market ROCTAVIAN.

(2) Refer to Non-GAAP Information beginning on page 10 of this press release for definitions of Non-GAAP Income, Non-GAAP Operating Margin percentage and Non-GAAP Diluted EPS along with the related reconciliations to the comparable information reported under U.S. GAAP.

(3) GAAP Operating Margin percentage is defined by the company as GAAP Income from Operations divided by Total Revenues.

Forward-Looking Non-GAAP Financial Information

BioMarin does not provide guidance for GAAP reported financial measures (other than revenue) or a reconciliation of forward-looking Non-GAAP financial measures to the most directly comparable GAAP reported financial measures because the company is unable to predict with reasonable certainty the financial impact of changes resulting from its strategic portfolio and business operating model reviews; potential future asset impairments; gains and losses on investments; and other unusual gains and losses without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. As such, any reconciliations provided would imply a degree of precision that could be confusing or misleading to investors.

Updated 2026 Full-Year Financial Guidance (in millions, except EPS amounts)

•Total Revenues, VOXZOGO, and Non-GAAP Diluted EPS guidance raised, reflecting strong first-half 2026 performance and second-half 2026 revenue expectations for both Metabolic Conditions and VOXZOGO.

•Guidance reflects post-close contributions from Amicus beginning April 27, 2026.

•BioMarin will continue to include interest expense related to the Amicus financing in both GAAP and Non‑GAAP financial results. Based on current rates, interest expense associated with the financing is estimated at approximately $200 million on an annualized basis, with Term Loans and Senior Notes scheduled to mature after 2030.

Item Provided on May 4, 2026

Updated August 6, 2026

Midpoint Growth (Y/Y)

Total Revenues $3,825 to $3,925 $3,875

$3,925 21%

Metabolic Conditions $2,725 to $2,775 Unchanged 31%

VOXZOGO $975 to $1,025 $1,000 to $1,050 11%

Other Revenues(1)

$100 to $125 Unchanged

Non-GAAP Diluted EPS (2)(3)(4)

$4.85 to $5.05 $4.90 to $5.10 59%

(1) Other Revenues includes KUVAN, ROCTAVIAN, and royalties.

(2) Refer to Non-GAAP Information beginning on page 10 of this press release for definition of Non-GAAP Diluted EPS.

(3) Non-GAAP Diluted EPS guidance assumes approximately 200 million Weighted-Average Diluted Shares Outstanding.

(4) Non-GAAP Diluted EPS guidance assumes a combined company tax rate of 22%.

BioMarin will host a conference call and webcast to discuss second quarter 2026 financial results today, Thursday, August 6, 2026, at 4:30 p.m. ET. This event can be accessed through this link or on the investor section of the BioMarin website at www.biomarin.com.

U.S./Canada Dial-in Number: 800-715-9871 Replay Dial-in Number: 800-770-2030

International Dial-in Number: 646-307-1963

Replay International Dial-in Number: 609-800-9909

Conference ID: 3551298

About BioMarin

BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. To learn more, please visit www.biomarin.com.

Forward-Looking Statements

This press release and the associated conference call and webcast contain forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc. (BioMarin), including, without limitation, statements about: future financial performance, including the expectations of Total Revenues, Non-GAAP Diluted EPS, Non-GAAP Operating Margin, gross leverage, operating cash flow and revenue compound annual growth rate (CAGR) for, in certain instances, the full-year 2026, fourth quarter and second half of 2026, and future periods, and the underlying drivers of those results, such as the expected demand and continued growth of BioMarin’s Metabolic Conditions portfolio, including PALYNZIQ, and VOXZOGO, and the expected impact of the acquisition of Amicus Therapeutics, Inc. (Amicus); the anticipated benefits of the acquisition of Amicus, including the expected amount and timing of cost synergies as well as expected revenue from the addition of GALAFOLD and POMBILITI + OPFOLDA, including BioMarin’s plans and expectations to accelerate growth through mid-2030s; BioMarin’s plans for investment in innovation and future growth; the timing of orders for commercial products; plans and expectations regarding the development, commercialization and commercial prospects of BioMarin’s product candidates and commercial products, including the prospects and timing of actions relating to clinical studies and trials and product approvals, such as study initiations, study advancements, data readouts, submissions, filings, approvals, and label expansions; the expected benefits and availability of BioMarin’s commercial products and product candidates, including with respect to the potential new indication for VOXZOGO in hypochondroplasia; and potential growth opportunities and trends, including the assumptions and expectations regarding total addressable patient population (TAPP) with respect to the conditions targeted by BioMarin’s product candidates and commercial products.

These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: BioMarin’s success in the commercialization of its commercial products; BioMarin’s ability to realize the anticipated benefits of any acquisitions; BioMarin’s ability to accurately estimate future financial performance; impacts of macroeconomic and other external factors on BioMarin’s operations, regulatory uncertainty, the impact of new or increased tariffs, other trade protection measures, and escalating trade tensions; geopolitical instability, wars and military conflicts; results and timing of current and planned preclinical studies and clinical trials and the release of data from those trials; BioMarin’s ability to successfully manufacture its commercial products and product candidates; the content and timing of decisions by the U.S. Food and Drug Administration, the European Medicines Agency, the European Commission and other regulatory authorities concerning each of the described products and product candidates; the market for each of these products; BioMarin’s ability to meet product demand; actual sales of BioMarin’s commercial products; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption “Risk Factors” in BioMarin's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, as such factors may be updated by any subsequent reports. Investors are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin®, VOXZOGO®, VIMIZIM®, NAGLAZYME®, PALYNZIQ®, BRINEURA®, KUVAN®, ROCTAVIAN®, GALAFOLD®, and POMBILITI® + OPFOLDA® are registered trademarks of BioMarin Pharmaceutical Inc., or its affiliates. ALDURAZYME® is a registered trademark of BioMarin/Genzyme LLC. All other brand names and service marks, trademarks and other trade names appearing in this release are the property of their respective owners.

BIOMARIN PHARMACEUTICAL INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

Three and Six Months Ended June 30, 2026 and 2025

(In thousands of U.S. dollars, except per share amounts)

(Unaudited)

Three Months Ended

June 30, Six Months Ended

June 30,

2026 2025 2026 2025

REVENUES:

Net product revenues $ 984,393 $ 812,982 $ 1,744,471 $ 1,547,626

Royalty and other revenues 5,315 12,428 11,445 22,929

Total revenues 989,708 825,410 1,755,916 1,570,555

OPERATING EXPENSES:

Cost of sales 202,795 150,090 397,794 301,648

Research and development 206,952 161,308 385,748 320,039

Selling, general and administrative 395,549 232,279 653,839 438,395

Intangible asset amortization 73,492 4,846 77,975 9,693

Total operating expenses 878,788 548,523 1,515,356 1,069,775

INCOME FROM OPERATIONS

110,920 276,887 240,560 500,780

Interest income 10,480 18,827 33,040 37,840

Interest expense (63,295) (2,679) (78,253) (5,542)

Other income, net 3,279 4,833 7,240 2,879

INCOME BEFORE INCOME TAXES

61,384 297,868 202,587 535,957

Provision for income taxes 16,622 57,336 52,298 109,739

NET INCOME

$ 44,762 $ 240,532 $ 150,289 $ 426,218

EARNINGS PER SHARE, BASIC

$ 0.23 $ 1.25 $ 0.78 $ 2.23

EARNINGS PER SHARE, DILUTED

$ 0.23 $ 1.23 $ 0.77 $ 2.19

Weighted average common shares outstanding, basic 193,423 191,907 192,959 191,440

Weighted average common shares outstanding, diluted 194,467 197,091 194,147 196,643

BIOMARIN PHARMACEUTICAL INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

June 30, 2026 and December 31, 2025

(In thousands of U.S. dollars, except per share amounts)

(Unaudited)

June 30, 2026 December 31, 2025

ASSETS

Current assets:

Cash and cash equivalents $ 874,005 $ 1,311,679

Short-term investments — 248,930

Accounts receivable, net 1,061,047 908,214

Inventory 1,782,524 1,298,883

Other current assets 254,047 185,784

Total current assets 3,971,623 3,953,490

Noncurrent assets:

Long-term investments — 492,242

Property, plant and equipment, net 989,994 952,508

Intangible assets, net 4,879,367 213,837

Goodwill 655,745 196,199

Deferred tax assets 888,575 1,508,697

Other assets 338,138 277,049

Total assets $ 11,723,442 $ 7,594,022

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:

Accounts payable and accrued liabilities $ 1,005,793 $ 759,031

Current portion of long-term debt, net 658,203 —

Total current liabilities 1,663,996 759,031

Noncurrent liabilities:

Long-term debt, net 3,527,939 597,176

Other long-term liabilities 209,815 150,816

Total liabilities 5,401,750 1,507,023

Stockholders’ equity:

Common stock, $0.001 par value: 500,000,000 shares authorized; 193,535,556 and 192,300,101 shares issued and outstanding, respectively

194 192

Additional paid-in capital 6,037,019 5,956,582

Company common stock held by the Nonqualified Deferred Compensation Plan (11,233) (10,508)

Accumulated other comprehensive income (loss) (8,783) (13,473)

Retained earnings

304,495 154,206

Total stockholders’ equity 6,321,692 6,086,999

Total liabilities and stockholders’ equity $ 11,723,442 $ 7,594,022

BIOMARIN PHARMACEUTICAL INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Six Months Ended June 30, 2026 and 2025

(In thousands of U.S. dollars)

(Unaudited)

Six Months Ended June 30,

2026 2025

CASH FLOWS FROM OPERATING ACTIVITIES:

Net income $ 150,289 $ 426,218

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization 114,049 40,632

Non-cash interest expense 27,912 1,320

Stock-based compensation 119,152 85,231

Impairment of assets — 2,967

Deferred income taxes 2,261 61,771

Unrealized foreign exchange gains (4,046) (5,306)

Other (5,534) (4,633)

Changes in operating assets and liabilities, net of effects of business acquired:

Accounts receivable, net (46,005) (156,124)

Inventory 12,334 (72,462)

Other current assets (23,589) (15,092)

Other assets 9,005 (13,505)

Accounts payable and accrued liabilities 26,265 3,111

Other long-term liabilities 6,667 5,537

Net cash provided by operating activities 388,760 359,665

CASH FLOWS FROM INVESTING ACTIVITIES:

Purchases of property, plant and equipment (49,739) (33,869)

Maturities and sales of investments 767,277 195,738

Purchases of investments (25,792) (202,433)

Purchase of intangible assets (5,433) (266)

Acquisition of Amicus, net of cash acquired (5,067,630) —

Other 4,966 —

Net cash used in investing activities (4,376,351) (40,830)

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from exercises of awards under equity incentive plans 6,655 7,707

Taxes paid related to net share settlement of equity awards (39,504) (51,089)

Proceeds from borrowings 3,650,000 —

Payments of debt issuance costs (65,604) —

Net cash provided by (used in) financing activities 3,551,547 (43,382)

Effect of exchange rate changes on cash (1,630) (4,479)

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS (437,674) 270,974

Cash and cash equivalents:

Beginning of period $ 1,311,679 $ 942,842

End of period $ 874,005 $ 1,213,816

Non-GAAP Information

The results presented in this press release include both GAAP information and Non-GAAP information. Non-GAAP Income is defined by the company as GAAP Net Income (Loss) excluding amortization, stock-based compensation expense and, in certain periods, certain other specified items, as detailed below when applicable. The company also includes a Non-GAAP adjustment for the estimated tax impact of the reconciling items. Non-GAAP Cost of Sales (COS), Non-GAAP R&D expenses and Non-GAAP Selling, General and Administrative (SG&A) expenses are defined by the company as GAAP COS, GAAP R&D expenses and GAAP SG&A expenses, respectively, excluding stock-based compensation expense and, in certain periods, certain other specified items, as detailed below when applicable. Non-GAAP Operating Margin percentage is defined by the company as GAAP Income (Loss) from Operations, excluding amortization of intangible assets, stock-based compensation expense and, in certain periods, certain other specified items, divided by GAAP Total Revenues. Non-GAAP Diluted EPS is defined by the company as Non-GAAP Income divided by Non-GAAP Weighted-Average Diluted Shares Outstanding. Non-GAAP Weighted-Average Diluted Shares Outstanding is defined by the company as GAAP Weighted-Average Diluted Shares Outstanding, adjusted to include any common shares issuable under the company’s equity plans or convertible debt in periods when they are dilutive under Non-GAAP. Projected Gross Leverage is defined by the company as undiscounted debt (total debt excluding unamortized discount and deferred offering costs) as of the balance sheet date divided by 4 quarter projected Non-GAAP Adjusted EBITDA. Non-GAAP Adjusted EBITDA is defined by the company as GAAP Income (or Loss) from Operations excluding the impact of depreciation, amortization and stock-based compensation expense. Non-GAAP synergies is defined by the company as Amicus’ legacy labor and external spend cost reductions, excluding the impact of stock-based compensation.

BioMarin regularly uses both GAAP and Non-GAAP results and expectations internally to assess its financial operating performance and evaluate key business decisions related to its principal business activities: the discovery, development, manufacture, marketing and sale of innovative biologic therapies. BioMarin also uses Non-GAAP Income internally to understand, manage and evaluate its business and to make operating decisions, and compensation of executives is based in part on this measure. Because these Non-GAAP metrics are important internal measurements for BioMarin, the company believes that providing this information in conjunction with BioMarin’s GAAP information enhances investors’ and analysts’ ability to meaningfully compare the company’s results from period to period and to its forward-looking guidance, and to identify operating trends in the company’s principal business.

Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for, or superior to comparable GAAP measures and should be read in conjunction with the consolidated financial information prepared in accordance with GAAP. Investors should note that the Non-GAAP information is not prepared under any comprehensive set of accounting rules or principles and does not reflect all of the amounts associated with the company’s results of operations as determined in accordance with GAAP. Investors should also note that these Non-GAAP financial measures have no standardized meaning prescribed by GAAP and, therefore, have limits in their usefulness to investors. In addition, from time to time in the future there may be other items that the company may exclude for purposes of its Non-GAAP financial measures; likewise, the company may in the future cease to exclude items that it has historically excluded for purposes of its Non-GAAP financial measures. Because of the non-standardized definitions, the Non-GAAP financial measure as used by BioMarin in this press release and the accompanying tables may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.

The following tables present the reconciliation of GAAP reported to Non-GAAP adjusted financial information:

Reconciliation of GAAP Reported Information to Non-GAAP Information (1)

(In millions of U.S. dollars, except per share data)

(unaudited)

Three Months Ended

June 30, Six Months Ended

June 30,

2026 2025 2026 2025

GAAP Reported Net Income $ 45 $ 241 $ 150 $ 426

Adjustments

Stock-based compensation expense - COS 5 4 9 6

Stock-based compensation expense - R&D 16 14 28 26

Stock-based compensation expense - SG&A(2)

55 30 83 53

Amortization of intangible assets 73 5 78 10

Amortization of acquired inventory step-up(3)

12 — 12 —

Acquisition-related costs(3)

84 — 84 —

Severance costs (4)

3 — 12 —

Loss on investments (5)

— — — 3

Income tax effect of adjustments (57) (11) (70) (22)

Non-GAAP Income $ 236 $ 282 $ 385 $ 502

Three Months Ended

June 30,

2026 2025

COS R&D SG&A COS R&D SG&A

GAAP expenses $ 203 $ 207 $ 396 $ 150 $ 161 $ 232

Adjustments

Stock-based compensation expense(2)

(5) (16) (55) (4) (14) (30)

Amortization of acquired inventory step-up(3)

(12) — — — — —

Acquisition-related costs (3)

— — (84) — — —

Severance costs (4)

— — (3) — — —

Non-GAAP expenses $ 186 $ 191 $ 253 $ 146 $ 147 $ 203

Six Months Ended

June 30,

2026 2025

COS R&D SG&A COS R&D SG&A

GAAP expenses $ 398 $ 386 $ 654 $ 302 $ 320 $ 438

Adjustments

Stock-based compensation expense(2)

(9) (28) (83) (6) (26) (53)

Amortization of acquired inventory step-up(3)

(12) — — — — —

Acquisition-related costs (3)

— — (84) — — —

Severance costs (4)

— — (12) — — —

Non-GAAP expenses $ 378 $ 358 $ 475 $ 295 $ 294 $ 385

Three Months Ended

June 30, Six Months Ended

June 30,

2026 Percent of GAAP Total Revenue 2025 Percent of GAAP Total Revenue 2026 Percent of GAAP Total Revenue 2025 Percent of GAAP Total Revenue

GAAP Income from Operations $ 111 11.2 % $ 277 33.5 % $ 241 13.7 % $ 501 31.9 %

Adjustments

Stock-based compensation expense(2)

76 7.7 48 5.8 120 6.8 85 5.4

Amortization of intangible assets 73 7.4 5 0.6 78 4.4 10 0.6

Amortization of acquired inventory step-up(3)

12 1.2 — — 12 0.7 — —

Acquisition-related costs (3)

84 8.5 — — 84 4.8 — —

Severance costs (4)

3 0.3 — — 12 0.7 — —

Non-GAAP Income from Operations $ 360 36.4 % $ 329 39.9 % $ 545 31.0 % $ 596 37.9 %

Three Months Ended

June 30, Six Months Ended

June 30,

2026 2025 2026 2025

GAAP Diluted EPS $ 0.23 $ 1.23 $ 0.77 $ 2.19

Adjustments

Stock-based compensation expense(2)

$ 0.38 $ 0.24 0.60 0.43

Amortization of intangible assets $ 0.37 $ 0.03 0.39 0.05

Amortization of acquired inventory step-up(3)

$ 0.06 $ — 0.06 —

Acquisition-related costs(3)

$ 0.42 $ — 0.42 —

Severance costs (4)

$ 0.02 $ — 0.06 —

Loss on investments (5)

$ — $ — — 0.02

Income tax effect of adjustments $ (0.29) $ (0.06) (0.35) (0.11)

Non-GAAP Diluted EPS $ 1.20 $ 1.44 $ 1.96 $ 2.57

Three Months Ended

June 30, Six Months Ended

June 30,

2026 2025 2026 2025

GAAP Weighted-Average Diluted Shares Outstanding 194.5 197.1 194.1 196.6

Adjustments

Common stock issuable under company’s convertible debt (6)

4.4 — 4.4 —

Non-GAAP Weighted-Average Diluted Shares Outstanding 198.9 197.1 198.5 196.6

(1) Certain amounts may not sum or recalculate due to rounding.

(2) Stock-based compensation expense recorded in SG&A for the three and six months ended June 30, 2026, includes approximately $13 million related to the post-combination service period for unvested Amicus stock options.

(3) These amounts represent costs resulting from the Amicus acquisition that closed on April 27, 2026. Acquisition-related costs were included in SG&A and consisted of severance, transaction and integration costs. Amortization of acquired inventory step-up was included in COS.

(4) These amounts were included in SG&A and represent charges for severance in connection with the company’s plan to simplify its organizational design and strategic initiatives in the first and second quarters of 2026.

(5) Represents impairment loss on non-marketable equity securities recorded in Other income, net, in the first quarter of 2025.

(6) Common stock issuable under the company’s convertible debt were excluded from the computation of GAAP Weighted-Average Diluted Shares Outstanding for the three and six months ended June 30, 2026 as they were anti-dilutive.

Amicus Therapeutics, Inc. (1)

Reconciliation of Non-GAAP Financial Measures

(in thousands)

(Unaudited)

Twelve Months Ended

December 31, 2025

Total operating expenses - as reported GAAP $ 528,492

Research and development:

Share-based compensation 12,156

Selling, general and administrative:

Share-based compensation 75,254

Loss on impairment of assets 1,702

Depreciation and amortization 7,460

Total operating expense adjustments to reported GAAP 96,572

Total operating expenses - as adjusted $ 431,920

(1)The above historical reconciliation is reproduced from Amicus’ earnings release furnished as Exhibit 99.1 to its Current Report on Form 8-K dated February 20, 2026 and reflects Amicus’ historical definitions of the applicable non-GAAP measures.

GRAPHIC

Filename: imagea.jpg · Sequence: 6

Binary file (198689 bytes)

Download imagea.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Document and Entity Information Document

Aug. 06, 2026

May 04, 2026

Cover [Abstract]

Document Type

8-K

Document Period End Date

Aug. 06, 2026

Entity Registrant Name

BioMarin Pharmaceutical Inc.

Entity Incorporation, State or Country Code

Entity File Number

000-26727

Entity Tax Identification Number

68-0397820

Entity Address, Address Line One

770 Lindaro Street

Entity Address, City or Town

San Rafael

Entity Address, State or Province

Entity Address, Postal Zip Code

94901

City Area Code

415

Local Phone Number

506-6700

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.001

Trading Symbol

BMRN

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

Amendment Flag

false

Entity Central Index Key

0001048477

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration